Creative medical technology granted fda clearance for chronic back pain clinical trial

New york, december 21, 2023 – creative medical technology holdings, inc. (nasdaq: celz) has received fda clearance to conduct a phase 1/2 clinical trial using the company's innovative stemspine® treatment known as allostem™ (celz-201-ddt).
CELZ Ratings Summary
CELZ Quant Ranking